Herpes Zoster Reports in Multiple Sclerosis Patients Treated With Disease Modifying Drugs – An Analysis of EudraVigilance Database
Rafal Kulakowski1, Michal Chrzanowski2, Maciej Niewada1, Dagmara Mirowska-Guzel1
1Medical University of Warsaw, 2Polish Society of Pharmacovigilance
Objective:
The aim of this study was to assess the number of reports of adverse Herpes Zoster (HZ) infections in multiple sclerosis (MS) patients, treated with different disease modifying therapies (DMTs), using data collected in EudraVigilance database.
Background:
MS itself as well as many currently available DMTs, with immunosuppressive mechanism of action, used in MS treatment are known to be risk factors for adverse HZ infection development. During HZ infection serious complications e.g. postherpetic neuralgia or herpes zoster ophthalmicus might develop, impacting significantly patients’ quality of life. The available data concerning HZ development in MS patients treated with DMTs is limited, highlighting the need for further investigation.
Design/Methods:
We reviewed EudraVigilance database to identify reported cases of HZ infection in MS patients receiving different DMTs. Reports from 2003-2024 were analyzed with computer programs such as: RStudio and Microsoft Excel. Reporting odds ratios (RORs) for the drugs were calculated, and Fisher's exact test was used to determine statistical significance (P-value < 0.05).
Results:
We identified 2017 reports of HZ infections, concerning MS patients treated with different DMTs. The percentage values of HZ reports varied significantly between different DMTs. Values form 0.2% (glatiramer acetate), to 3.9% (cladribine) of all adverse reports, mark HZ as a relevant complication during MS treatment. The highest ROR values were noted for fingolimod (4,09), cladribine (3,33) and alemtuzumab (2,27), followed by siponimod (1,97). The lowest RORs were calculated for glatiramer acetate (0,17), interferons (≈0,21) and teriflunomide (0,35).
Conclusions:
Our study shows that some DMTs used in MS might be linked with significant increase in the risk of HZ infection development. While treating MS patient with DMTs, clinicians should always carefully evaluate the risk of adverse HZ. Moreover, vaccination against HZ should be recommended, to reduce the risk of HZ infection, enabling patients to benefit fully form the available MS treatment.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.